Gilead Sciences, Inc. [GILD] stock prices are up 1.46% to $68.75 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GILD shares have gain 0.51% over the last week, with a monthly amount glided 6.26%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Gilead Sciences, Inc. [NASDAQ: GILD] stock has seen the most recent analyst activity on July 08, 2024, when Raymond James upgraded its rating to a Outperform but kept the price target unchanged to $93 for it. Previously, Maxim Group reaffirmed its Buy rating on May 01, 2024, and dropped its price target to $85. On April 24, 2024, upgrade upgraded it’s rating to Hold but maintained its price target of $69 on the stock. Truist downgraded its rating to a Hold and decreased its price target to $82 on February 22, 2024. Deutsche Bank initiated its recommendation with a Hold and recommended $75 as its price target on November 09, 2023. BofA Securities upgraded its rating to Buy for this stock on September 08, 2023, and upped its price target to $95. In a note dated September 06, 2023, HSBC Securities initiated an Reduce rating and provided a target price of $71 on this stock.
The stock price of Gilead Sciences, Inc. [GILD] has been fluctuating between $62.07 and $87.86 over the past year. Currently, Wall Street analysts expect the stock to reach $81.5 within the next 12 months. Gilead Sciences, Inc. [NASDAQ: GILD] shares were valued at $68.75 at the most recent close of the market. An investor can expect a potential return of 18.55% based on the average GILD price forecast.
Analyzing the GILD fundamentals
The Gilead Sciences, Inc. [NASDAQ:GILD] reported sales of 27.42B for trailing twelve months, representing a surge of 5.66%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.33%, Pretax Profit Margin comes in at 0.04%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.02 and Total Capital is 0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 67.98 points at the first support level, and at 67.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 69.19, and for the 2nd resistance point, it is at 69.63.
Ratios To Look Out For
It’s worth pointing out that Gilead Sciences, Inc. [NASDAQ:GILD]’s Current Ratio is 1.08. In addition, the Quick Ratio stands at 0.94 and the Cash Ratio stands at 0.36. Considering the valuation of this stock, the price to sales ratio is 3.12, the price to book ratio is 4.88 and price to earnings (TTM) ratio is 191.66.
Transactions by insiders
Recent insider trading involved Parsey Merdad, Chief Medical Officer, that happened on Jul 01 ’24 when 2000.0 shares were sold. 10% Owner, GILEAD SCIENCES, INC. completed a deal on Apr 02 ’24 to buy 0.49 million shares. Meanwhile, Chief Medical Officer Parsey Merdad sold 2000.0 shares on Apr 01 ’24.
